Clinical trial news

Spinraza motor milestones Discussion

Infants with Spinal Muscular Atrophy (SMA) who do not yet show symptoms experience numerous benefits from Spinraza (nusinersen) treatment, according to data that Biogen will present at the Cure SMA 2017 Annual Conference in Orlando, Florida on June 29 to July 2. Among the host of presentations that the company…

defining Discussion

Cure SMA announced the start of Phase 2 of its SMA Industry Collaboration, aiming to advance the development of specific goals. “The SMA Industry Collaboration is a multifaceted partnership that brings together pharmaceutical companies, Cure SMA, and other nonprofit organizations, to share information, ideas, and data,” according to a…

The pharmaceutical company AveXis recently presented the latest data about its clinical trial for AVXS-101, a gene therapy for infants with type 1 SMA. The one-time infusion is designed to correct the faulty gene responsible for spinal muscular atrophy, using a harmless virus able to cross the brain-blood barrier. MORE: Gene therapy may…